Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.

Gunnar H Gislason; Søren Jacobsen; Jeppe Nørgaard Rasmussen; Søren Rasmussen; Pernille Buch; Jens Friberg; Tina Ken Schramm; Steen Z Abildstrom; Lars Køber; Mette Madsen; Christian Torp-Pedersen

doi:10.1161/CIRCULATIONAHA.106.616219

Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.

Gunnar H Gislason, Søren Jacobsen, Jeppe Nørgaard Rasmussen, Søren Rasmussen, Pernille Buch, Jens Friberg, Tina Ken Schramm, Steen Z Abildstrom, Lars Køber, Mette Madsen, Christian Torp-Pedersen

Department of Public Health

348 Citations (Scopus)

Abstract

BACKGROUND: The selective cyclooxygenase-2 (COX-2) inhibitors and other nonselective nonsteroidal antiinflammatory drugs (NSAIDs) have been associated with increased cardiovascular risk, but the risk in patients with established cardiovascular disease is unknown. We analyzed the risk of rehospitalization for acute myocardial infarction (MI) and death related to the use of NSAIDs including selective COX-2 inhibitors in patients with prior MI. METHODS AND RESULTS: All patients with first-time MI between 1995 and 2002 as well as all prescription claims for NSAIDs after discharge were identified from nationwide Danish administrative registers. The risk of death and rehospitalization for MI associated with the use of selective COX-2 inhibitors and nonselective NSAIDs was studied with the use of multivariable proportional hazards models and case-crossover analysis. A total of 58 432 patients were discharged alive and included in the study; 9773 experienced rehospitalization for MI, and 16 573 died. A total of 5.2% of patients received rofecoxib, 4.3% celecoxib, 17.5% ibuprofen, 10.6% diclofenac, and 12.7% other NSAIDs. For any use of rofecoxib, celecoxib, ibuprofen, diclofenac, and other NSAIDs, the hazard ratios and 95% confidence intervals for death were 2.80 (2.41 to 3.25; for rofecoxib), 2.57 (2.15 to 3.08; for celecoxib), 1.50 (1.36 to 1.67; for ibuprofen), 2.40 (2.09 to 2.80; for diclofenac), and 1.29 (1.16 to 1.43; for other NSAIDS); there were dose-related increases in risk of death for all of the drugs. There were trends for increased risk of rehospitalization for MI associated with the use of both the selective COX-2 inhibitors and the nonselective NSAIDs. CONCLUSIONS: Selective COX-2 inhibitors in all dosages and nonselective NSAIDs in high dosages increase mortality in patients with previous MI and should therefore be used with particular caution in these patients.
Udgivelsesdato: 2006-Jun-27

Original language	English
Journal	Circulation
Volume	113
Issue number	25
Pages (from-to)	2906-13
Number of pages	7
ISSN	0009-7322
DOIs	https://doi.org/10.1161/CIRCULATIONAHA.106.616219
Publication status	Published - 2006

Access to Document

10.1161/CIRCULATIONAHA.106.616219

Cite this

Gislason, G. H., Jacobsen, S., Rasmussen, J. N., Rasmussen, S., Buch, P., Friberg, J., Schramm, T. K., Abildstrom, S. Z., Køber, L., Madsen, M., & Torp-Pedersen, C. (2006). Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. Circulation, 113(25), 2906-13. https://doi.org/10.1161/CIRCULATIONAHA.106.616219

Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction. / Gislason, Gunnar H; Jacobsen, Søren; Rasmussen, Jeppe Nørgaard et al.

In: Circulation, Vol. 113, No. 25, 2006, p. 2906-13.

Research output: Contribution to journal › Journal article › Research › peer-review

Gislason, GH, Jacobsen, S, Rasmussen, JN, Rasmussen, S, Buch, P, Friberg, J, Schramm, TK, Abildstrom, SZ, Køber, L , Madsen, M & Torp-Pedersen, C 2006, 'Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.', Circulation, vol. 113, no. 25, pp. 2906-13. https://doi.org/10.1161/CIRCULATIONAHA.106.616219

@article{932ad5b0ff6511dcbee902004c4f4f50,

title = "Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.",

abstract = "BACKGROUND: The selective cyclooxygenase-2 (COX-2) inhibitors and other nonselective nonsteroidal antiinflammatory drugs (NSAIDs) have been associated with increased cardiovascular risk, but the risk in patients with established cardiovascular disease is unknown. We analyzed the risk of rehospitalization for acute myocardial infarction (MI) and death related to the use of NSAIDs including selective COX-2 inhibitors in patients with prior MI. METHODS AND RESULTS: All patients with first-time MI between 1995 and 2002 as well as all prescription claims for NSAIDs after discharge were identified from nationwide Danish administrative registers. The risk of death and rehospitalization for MI associated with the use of selective COX-2 inhibitors and nonselective NSAIDs was studied with the use of multivariable proportional hazards models and case-crossover analysis. A total of 58 432 patients were discharged alive and included in the study; 9773 experienced rehospitalization for MI, and 16 573 died. A total of 5.2% of patients received rofecoxib, 4.3% celecoxib, 17.5% ibuprofen, 10.6% diclofenac, and 12.7% other NSAIDs. For any use of rofecoxib, celecoxib, ibuprofen, diclofenac, and other NSAIDs, the hazard ratios and 95% confidence intervals for death were 2.80 (2.41 to 3.25; for rofecoxib), 2.57 (2.15 to 3.08; for celecoxib), 1.50 (1.36 to 1.67; for ibuprofen), 2.40 (2.09 to 2.80; for diclofenac), and 1.29 (1.16 to 1.43; for other NSAIDS); there were dose-related increases in risk of death for all of the drugs. There were trends for increased risk of rehospitalization for MI associated with the use of both the selective COX-2 inhibitors and the nonselective NSAIDs. CONCLUSIONS: Selective COX-2 inhibitors in all dosages and nonselective NSAIDs in high dosages increase mortality in patients with previous MI and should therefore be used with particular caution in these patients. Udgivelsesdato: 2006-Jun-27",

author = "Gislason, {Gunnar H} and S{\o}ren Jacobsen and Rasmussen, {Jeppe N{\o}rgaard} and S{\o}ren Rasmussen and Pernille Buch and Jens Friberg and Schramm, {Tina Ken} and Abildstrom, {Steen Z} and Lars K{\o}ber and Mette Madsen and Christian Torp-Pedersen",

note = "Keywords: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Denmark; Diclofenac; Dose-Response Relationship, Drug; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Patient Readmission; Proportional Hazards Models; Pyrazoles; Recurrence; Registries; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones",

year = "2006",

doi = "10.1161/CIRCULATIONAHA.106.616219",

language = "English",

volume = "113",

pages = "2906--13",

journal = "Circulation",

issn = "0009-7322",

publisher = "AHA/ASA",

number = "25",

}

TY - JOUR

T1 - Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective nonsteroidal antiinflammatory drugs after acute myocardial infarction.

AU - Gislason, Gunnar H

AU - Jacobsen, Søren

AU - Rasmussen, Jeppe Nørgaard

AU - Rasmussen, Søren

AU - Buch, Pernille

AU - Friberg, Jens

AU - Schramm, Tina Ken

AU - Abildstrom, Steen Z

AU - Køber, Lars

AU - Madsen, Mette

AU - Torp-Pedersen, Christian

N1 - Keywords: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Confidence Intervals; Cross-Over Studies; Cyclooxygenase 2 Inhibitors; Denmark; Diclofenac; Dose-Response Relationship, Drug; Female; Humans; Ibuprofen; Lactones; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Patient Readmission; Proportional Hazards Models; Pyrazoles; Recurrence; Registries; Retrospective Studies; Risk Factors; Sulfonamides; Sulfones

PY - 2006

Y1 - 2006

N2 - BACKGROUND: The selective cyclooxygenase-2 (COX-2) inhibitors and other nonselective nonsteroidal antiinflammatory drugs (NSAIDs) have been associated with increased cardiovascular risk, but the risk in patients with established cardiovascular disease is unknown. We analyzed the risk of rehospitalization for acute myocardial infarction (MI) and death related to the use of NSAIDs including selective COX-2 inhibitors in patients with prior MI. METHODS AND RESULTS: All patients with first-time MI between 1995 and 2002 as well as all prescription claims for NSAIDs after discharge were identified from nationwide Danish administrative registers. The risk of death and rehospitalization for MI associated with the use of selective COX-2 inhibitors and nonselective NSAIDs was studied with the use of multivariable proportional hazards models and case-crossover analysis. A total of 58 432 patients were discharged alive and included in the study; 9773 experienced rehospitalization for MI, and 16 573 died. A total of 5.2% of patients received rofecoxib, 4.3% celecoxib, 17.5% ibuprofen, 10.6% diclofenac, and 12.7% other NSAIDs. For any use of rofecoxib, celecoxib, ibuprofen, diclofenac, and other NSAIDs, the hazard ratios and 95% confidence intervals for death were 2.80 (2.41 to 3.25; for rofecoxib), 2.57 (2.15 to 3.08; for celecoxib), 1.50 (1.36 to 1.67; for ibuprofen), 2.40 (2.09 to 2.80; for diclofenac), and 1.29 (1.16 to 1.43; for other NSAIDS); there were dose-related increases in risk of death for all of the drugs. There were trends for increased risk of rehospitalization for MI associated with the use of both the selective COX-2 inhibitors and the nonselective NSAIDs. CONCLUSIONS: Selective COX-2 inhibitors in all dosages and nonselective NSAIDs in high dosages increase mortality in patients with previous MI and should therefore be used with particular caution in these patients. Udgivelsesdato: 2006-Jun-27

AB - BACKGROUND: The selective cyclooxygenase-2 (COX-2) inhibitors and other nonselective nonsteroidal antiinflammatory drugs (NSAIDs) have been associated with increased cardiovascular risk, but the risk in patients with established cardiovascular disease is unknown. We analyzed the risk of rehospitalization for acute myocardial infarction (MI) and death related to the use of NSAIDs including selective COX-2 inhibitors in patients with prior MI. METHODS AND RESULTS: All patients with first-time MI between 1995 and 2002 as well as all prescription claims for NSAIDs after discharge were identified from nationwide Danish administrative registers. The risk of death and rehospitalization for MI associated with the use of selective COX-2 inhibitors and nonselective NSAIDs was studied with the use of multivariable proportional hazards models and case-crossover analysis. A total of 58 432 patients were discharged alive and included in the study; 9773 experienced rehospitalization for MI, and 16 573 died. A total of 5.2% of patients received rofecoxib, 4.3% celecoxib, 17.5% ibuprofen, 10.6% diclofenac, and 12.7% other NSAIDs. For any use of rofecoxib, celecoxib, ibuprofen, diclofenac, and other NSAIDs, the hazard ratios and 95% confidence intervals for death were 2.80 (2.41 to 3.25; for rofecoxib), 2.57 (2.15 to 3.08; for celecoxib), 1.50 (1.36 to 1.67; for ibuprofen), 2.40 (2.09 to 2.80; for diclofenac), and 1.29 (1.16 to 1.43; for other NSAIDS); there were dose-related increases in risk of death for all of the drugs. There were trends for increased risk of rehospitalization for MI associated with the use of both the selective COX-2 inhibitors and the nonselective NSAIDs. CONCLUSIONS: Selective COX-2 inhibitors in all dosages and nonselective NSAIDs in high dosages increase mortality in patients with previous MI and should therefore be used with particular caution in these patients. Udgivelsesdato: 2006-Jun-27

U2 - 10.1161/CIRCULATIONAHA.106.616219

DO - 10.1161/CIRCULATIONAHA.106.616219

M3 - Journal article

C2 - 16785336

SN - 0009-7322

VL - 113

SP - 2906

EP - 2913

JO - Circulation

JF - Circulation

IS - 25

ER -